trending Market Intelligence /marketintelligence/en/news-insights/trending/blUy0Fi3M16AM7A5Z9D5CA2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

French biopharma Advicenne plans secondary listing on Euronext Brussels

Blog

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Video

Climate Credit Analytics: Linking climate scenarios to financial impacts

Blog

Global M&A Infographic Q1 2021

Blog

Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge


French biopharma Advicenne plans secondary listing on Euronext Brussels

France's Advicenne SA, a biopharmaceutical company developing therapies for orphan diseases, is planning a secondary listing on the Euronext Brussels stock exchange.

The company's ordinary shares are currently listed on the Euronext Paris stock exchange and would be cross listed on the Euronext Brussels if the proposed listing is approved. Euronext Paris will remain as the company's primary listing venue.

The cross listing will increase the visibility of Advicenne's shares in Belgium and beyond, the company said in a news release. Advicenne is conducting a phase 2/3 study of its lead product ADV7103 in Belgium for treating cystinuria, a rare kidney disease.

The cross listing would have no impact on Advicenne's current shareholders.